Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.COVID-19 vaccination protected bullous pemphigoid patients from infection and severity. However, high-dose prednisone use increased infection risk, highlighting crucial management considerations for this vulnerable population.
Area Of Science
- Dermatology
- Infectious Diseases
- Immunology
Background
- Bullous pemphigoid (BP) patient outcomes with COVID-19 are not well understood.
- Evaluating COVID-19's impact on BP patients is crucial.
- Identifying risk and severity factors for SARS-CoV-2 in BP patients is needed.
Purpose Of The Study
- To assess the impact of COVID-19 on bullous pemphigoid patients.
- To determine factors influencing SARS-CoV-2 infection risk and severity in BP patients.
Main Methods
- Cross-sectional survey of 96 BP patients from December 2022 to March 2023.
- Questionnaires collected data on demographics, medical history, and COVID-19 experiences.
- Logistic regression analyzed factors affecting SARS-CoV-2 infection risk and severity.
Main Results
- Vaccination significantly reduced SARS-CoV-2 infection risk (OR: 0.157) and severity (OR: 0.044).
- Prednisone use (>10 mg/day) in the last 3 months increased infection risk (OR: 7.911).
- High-dose prednisone did not significantly impact COVID-19 infection severity.
Conclusions
- COVID-19 vaccination is protective for BP patients against SARS-CoV-2 infection and severe disease.
- High-dose prednisone (>10 mg/day) is a risk factor for SARS-CoV-2 infection in BP patients.
- These findings inform management strategies for BP patients during pandemics.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
